Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + Toripalimab as neoadjuvant therapy for resectable stage II–IIIA NSCLC (Phase II)
ChiCTR2600122444Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shandong First Medical University. Primary endpoint: Pathological complete remission rate (pCR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122444.